Meningococcal (group B) multicomponent recombinant adsorbed vaccine

BIOLOGICAL2 trials

Sponsors

Novartis Vaccines, Novartis

Conditions

Meningitis, Meningococcal, Serogroup BMeningococcal DiseaseMeningococcal Meningitis

Phase 2

Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY Combination Vaccine in Adolescents Who Previously Received the Same Study Vaccines

CompletedNCT01367158

Novartis VaccinesMeningococcal Disease, Meningococcal Meningitis

Start: 2011-07-31End: 2012-07-31Updated: 2014-11-19

Phase 3

Safety and Blood Donations in Adults Vaccinated With rMenB+OMV NZ.

CompletedNCT02305446

NovartisMeningitis, Meningococcal, Serogroup B

Start: 2014-12-31End: 2015-04-30Updated: 2016-01-05

Related Papers

Four-year antibody persistence and response to a booster dose of a pentavalent MenABCWY vaccine administered to healthy adolescents and young adults

Human Vaccines & Immunotherapeutics2018-03-3023 citations